Clinical trials: Glioma Glioblastoma Multiforme
Glioblastoma, Glioblastoma Multiforme
Treatment of Recurrent GBM With APG-157 Via Expanded Access
This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.
- Trial name
- NCT05551013
- Testing
- APG-157
- Sponsor
- Aveta Biomics, Inc.
Glioblastoma Multiforme
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM…
- Trial name
- NCT00916409
- Testing
- NovoTTF-100A device, Temozolomide
- Where
- 89 sites in United States, Austria and 10 more
- Volunteers
- 700 people
- Sponsor
- NovoCure Ltd.
Glioblastoma
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
- Trial name
- NCT03491683
- Testing
- INO-5401, INO-9012, Cemiplimab
- Where
- 21 sites in United States
- Volunteers
- 52 people
- Sponsor
- Inovio Pharmaceuticals
Glioma, Glioblastoma
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma.
- Conditions
- Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma
- Trial name
- NCT00080054
- Testing
- Motexafin Gadolinium Injection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pharmacyclics LLC.
Glioblastoma Multiforme
UNITE Study: Understanding New Interventions With GBM ThErapy
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor…
- Trial name
- NCT03419403
- Testing
- Steroid eye drops, Vasoconstrictor eye drops, Cold compress
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma
- Trial name
- NCT02365662
- Testing
- ABBV-221
- Where
- 5 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- AbbVie
Recurrent Glioblastoma
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
Study Design - Multicenter, open-label, 3 arms, stepwise, phase Ⅱa clinical trial Study objective: 1. Primary - To evaluate the safety of TTAC-0001 in patients with recurrent glioblastoma. 2.
- Trial name
- NCT03033524
- Testing
- TTAC-0001
- Volunteers
- 12 people
- Sponsor
- PharmAbcine
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Glioblastoma Multiforme, Glioblastoma
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT06329570
- Testing
- NaviFUS System, Lumason, Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NaviFUS Corporation
Glioblastoma (GBM)
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt).
- Trial name
- NCT06805305
- Testing
- DOC1021, Tumor resection, Temodar (Temozolomide)
- Where
- 18 sites in United States
- Volunteers
- 180 people
- Sponsor
- Diakonos Oncology Corporation
Glioma, Astrocytoma
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12…
- Conditions
- Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma
- Trial name
- NCT00392171
- Testing
- Temozolomide
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma Multiforme
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
This is a safety study of tandutinib in combination with temozolomide and bevacizumab after people have received radiation therapy and temozolomide treatment.
- Trial name
- NCT00904852
- Testing
- Tandutinib, bevacizumab, and temozolomide
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Recurrent Glioblastoma
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.
- Trial name
- NCT05191784
- Testing
- GX-I7, Bevacizumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Genexine, Inc.
Glioblastoma
A Study in Recurrent Glioblastoma (GB)
The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer
- Trial name
- NCT01582269
- Testing
- Galunisertib, Lomustine
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Glioma, Glioblastoma
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to…
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT02717962
- Testing
- VAL-083, Dianhydrogalactitol
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Kintara Therapeutics, Inc.
Glioma of Brain
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
- Trial name
- NCT03650257
- Testing
- gp96, Temozolomide, radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Cure&Sure Biotech Co., LTD
Glioblastoma Multiforme
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
This study will evaluate if a drug called G-202 can be safely used to treat people with glioblastoma (GBM) that has progressed or recurred. G-202 is given by intravenous infusion on three consecutive days of a 28-day cycle.
- Trial name
- NCT02067156
- Testing
- G-202
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- GenSpera, Inc.
Glioblastoma Multiforme, Glioma of Brain
V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer
The Phase II study to determine the safety and efficacy of V-Boost in treating a type of brain cancer called Glioblastoma Multiforme (GBM).
- Trial name
- GBM (NCT03916757)
- Testing
- V-Boost
- Where
- Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Malignant Tumor, Advanced Solid Tumor
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna…
- Conditions
- Malignant Tumor, Advanced Solid Tumor, Glioblastoma Multiforme, Metastatic Cancer
- Trial name
- PhAST (NCT05495295)
- Testing
- PhOx430
- Where
- 4 sites in France, Italy
- Volunteers
- 149 people
- Sponsor
- Phost'In Therapeutics